Paul Thomen

Monday, 15 July 2013

Mania, Nocturia & Osteopenia Therapeutics Market Pipeline Review H1 2013 adds “Osteopenia – Pipeline Review, H1 2013” “Mania – Pipeline Review, H1 2013” and “Nocturia – Pipeline Review, H1 2013” on its database.

‘Mania, Nocturia & Osteopenia – Pipeline Review, H1 2013, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mania, Nocturia & Osteopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mania, Nocturia & Osteopenia. Mania, Nocturia & Osteopenia – Pipeline Review, Half Year is built using data and information.


- A snapshot of the global therapeutic scenario for Mania, Nocturia & Osteopenia.
- A review of the Mania, Nocturia & Osteopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mania, Nocturia & Osteopenia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Mania, Nocturia & Osteopenia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mania, Nocturia & Osteopenia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Content

Companies Involved in Osteopenia Therapeutics Development
Amgen Inc.
Novartis AG
Pfizer Inc.

Companies Involved in Mania Therapeutics Development
Gedeon Richter Plc.
Newron Pharmaceuticals S.p.A.
Reviva Pharmaceuticals Inc.

Companies Involved in Nocturia Therapeutics Development
Allergan, Inc.
Urigen Pharmaceuticals, Inc.
Vantia Therapeutics
Drais Pharmaceuticals, Inc.

Explore More Reports @

No comments:

Post a Comment

Note: only a member of this blog may post a comment.